Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses

Thomas Geisbert, Kathleen M. Daddario-DiCaprio, Joan B. Geisbert, Douglas S. Reed, Friederike Feldmann, Allen Grolla, Ute Ströher, Elizabeth A. Fritz, Lisa E. Hensley, Steven M. Jones, Heinz Feldmann

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Considerable progress has been made over the last decade in developing candidate preventive vaccines that can protect nonhuman primates against Ebola and Marburg viruses. A vaccine based on recombinant vesicular stomatitis virus (VSV) seems to be particularly robust as it can also confer protection when administered as a postexposure treatment. While filoviruses are not thought to be transmitted by aerosol in nature the inhalation route is among the most likely portals of entry in the setting of a bioterrorist event. At present, all candidate filoviral vaccines have been evaluated against parenteral challenges but none have been tested against an aerosol exposure. Here, we evaluated our recombinant VSV-based Zaire ebolavirus (ZEBOV) and Marburg virus (MARV) vaccines against aerosol challenge in cynomolgus macaques. All monkeys vaccinated with a VSV vector expressing the glycoprotein of ZEBOV were completely protected against an aerosol exposure of ZEBOV. Likewise, all monkeys vaccinated with a VSV vector expressing the glycoprotein of MARV were completely protected against an aerosol exposure of MARV. All control animals challenged by the aerosol route with either ZEBOV or MARV succumbed. Interestingly, disease in control animals appeared to progress slower than previously seen in macaques exposed to comparable doses by intramuscular injection.

Original languageEnglish (US)
Pages (from-to)6894-6900
Number of pages7
JournalVaccine
Volume26
Issue number52
DOIs
StatePublished - Dec 9 2008
Externally publishedYes

Fingerprint

Marburg virus
Marburgvirus
Ebolavirus
Vesiculovirus
Vesicular Stomatitis
Zaire Ebola virus
aerosols
Aerosols
Primates
Democratic Republic of the Congo
Vaccines
vaccines
Viruses
Macaca
Haplorhini
monkeys
glycoproteins
Glycoproteins
Filoviridae
Macaca fascicularis

Keywords

  • Aerosol
  • Ebola virus
  • Filovirus
  • Marburg virus
  • Nonhuman primates
  • Vaccines

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Geisbert, T., Daddario-DiCaprio, K. M., Geisbert, J. B., Reed, D. S., Feldmann, F., Grolla, A., ... Feldmann, H. (2008). Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine, 26(52), 6894-6900. https://doi.org/10.1016/j.vaccine.2008.09.082

Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. / Geisbert, Thomas; Daddario-DiCaprio, Kathleen M.; Geisbert, Joan B.; Reed, Douglas S.; Feldmann, Friederike; Grolla, Allen; Ströher, Ute; Fritz, Elizabeth A.; Hensley, Lisa E.; Jones, Steven M.; Feldmann, Heinz.

In: Vaccine, Vol. 26, No. 52, 09.12.2008, p. 6894-6900.

Research output: Contribution to journalArticle

Geisbert, T, Daddario-DiCaprio, KM, Geisbert, JB, Reed, DS, Feldmann, F, Grolla, A, Ströher, U, Fritz, EA, Hensley, LE, Jones, SM & Feldmann, H 2008, 'Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses', Vaccine, vol. 26, no. 52, pp. 6894-6900. https://doi.org/10.1016/j.vaccine.2008.09.082
Geisbert, Thomas ; Daddario-DiCaprio, Kathleen M. ; Geisbert, Joan B. ; Reed, Douglas S. ; Feldmann, Friederike ; Grolla, Allen ; Ströher, Ute ; Fritz, Elizabeth A. ; Hensley, Lisa E. ; Jones, Steven M. ; Feldmann, Heinz. / Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. In: Vaccine. 2008 ; Vol. 26, No. 52. pp. 6894-6900.
@article{7c71af6dd2c149899292d6e114a30d44,
title = "Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses",
abstract = "Considerable progress has been made over the last decade in developing candidate preventive vaccines that can protect nonhuman primates against Ebola and Marburg viruses. A vaccine based on recombinant vesicular stomatitis virus (VSV) seems to be particularly robust as it can also confer protection when administered as a postexposure treatment. While filoviruses are not thought to be transmitted by aerosol in nature the inhalation route is among the most likely portals of entry in the setting of a bioterrorist event. At present, all candidate filoviral vaccines have been evaluated against parenteral challenges but none have been tested against an aerosol exposure. Here, we evaluated our recombinant VSV-based Zaire ebolavirus (ZEBOV) and Marburg virus (MARV) vaccines against aerosol challenge in cynomolgus macaques. All monkeys vaccinated with a VSV vector expressing the glycoprotein of ZEBOV were completely protected against an aerosol exposure of ZEBOV. Likewise, all monkeys vaccinated with a VSV vector expressing the glycoprotein of MARV were completely protected against an aerosol exposure of MARV. All control animals challenged by the aerosol route with either ZEBOV or MARV succumbed. Interestingly, disease in control animals appeared to progress slower than previously seen in macaques exposed to comparable doses by intramuscular injection.",
keywords = "Aerosol, Ebola virus, Filovirus, Marburg virus, Nonhuman primates, Vaccines",
author = "Thomas Geisbert and Daddario-DiCaprio, {Kathleen M.} and Geisbert, {Joan B.} and Reed, {Douglas S.} and Friederike Feldmann and Allen Grolla and Ute Str{\"o}her and Fritz, {Elizabeth A.} and Hensley, {Lisa E.} and Jones, {Steven M.} and Heinz Feldmann",
year = "2008",
month = "12",
day = "9",
doi = "10.1016/j.vaccine.2008.09.082",
language = "English (US)",
volume = "26",
pages = "6894--6900",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "52",

}

TY - JOUR

T1 - Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses

AU - Geisbert, Thomas

AU - Daddario-DiCaprio, Kathleen M.

AU - Geisbert, Joan B.

AU - Reed, Douglas S.

AU - Feldmann, Friederike

AU - Grolla, Allen

AU - Ströher, Ute

AU - Fritz, Elizabeth A.

AU - Hensley, Lisa E.

AU - Jones, Steven M.

AU - Feldmann, Heinz

PY - 2008/12/9

Y1 - 2008/12/9

N2 - Considerable progress has been made over the last decade in developing candidate preventive vaccines that can protect nonhuman primates against Ebola and Marburg viruses. A vaccine based on recombinant vesicular stomatitis virus (VSV) seems to be particularly robust as it can also confer protection when administered as a postexposure treatment. While filoviruses are not thought to be transmitted by aerosol in nature the inhalation route is among the most likely portals of entry in the setting of a bioterrorist event. At present, all candidate filoviral vaccines have been evaluated against parenteral challenges but none have been tested against an aerosol exposure. Here, we evaluated our recombinant VSV-based Zaire ebolavirus (ZEBOV) and Marburg virus (MARV) vaccines against aerosol challenge in cynomolgus macaques. All monkeys vaccinated with a VSV vector expressing the glycoprotein of ZEBOV were completely protected against an aerosol exposure of ZEBOV. Likewise, all monkeys vaccinated with a VSV vector expressing the glycoprotein of MARV were completely protected against an aerosol exposure of MARV. All control animals challenged by the aerosol route with either ZEBOV or MARV succumbed. Interestingly, disease in control animals appeared to progress slower than previously seen in macaques exposed to comparable doses by intramuscular injection.

AB - Considerable progress has been made over the last decade in developing candidate preventive vaccines that can protect nonhuman primates against Ebola and Marburg viruses. A vaccine based on recombinant vesicular stomatitis virus (VSV) seems to be particularly robust as it can also confer protection when administered as a postexposure treatment. While filoviruses are not thought to be transmitted by aerosol in nature the inhalation route is among the most likely portals of entry in the setting of a bioterrorist event. At present, all candidate filoviral vaccines have been evaluated against parenteral challenges but none have been tested against an aerosol exposure. Here, we evaluated our recombinant VSV-based Zaire ebolavirus (ZEBOV) and Marburg virus (MARV) vaccines against aerosol challenge in cynomolgus macaques. All monkeys vaccinated with a VSV vector expressing the glycoprotein of ZEBOV were completely protected against an aerosol exposure of ZEBOV. Likewise, all monkeys vaccinated with a VSV vector expressing the glycoprotein of MARV were completely protected against an aerosol exposure of MARV. All control animals challenged by the aerosol route with either ZEBOV or MARV succumbed. Interestingly, disease in control animals appeared to progress slower than previously seen in macaques exposed to comparable doses by intramuscular injection.

KW - Aerosol

KW - Ebola virus

KW - Filovirus

KW - Marburg virus

KW - Nonhuman primates

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=56649099057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56649099057&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.09.082

DO - 10.1016/j.vaccine.2008.09.082

M3 - Article

VL - 26

SP - 6894

EP - 6900

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 52

ER -